Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis.

Zaccardi F, Htike ZZ, Webb DR, Khunti K, Davies MJ

Annals of internal medicine8 Dec 2015Cited by 65 (Europe PMC)

PMID26642233DOI10.7326/m15-1432PepBankPUB-26642233

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

01HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled once-weekly GLP-1 receptor agonists reduced HbA1c compared with placebo.
In plain wordsIn adults with type 2 diabetes, once-weekly GLP-1 drugs as a class lowered HbA1c more than placebo.
Peptide
Semaglutide
Outcome
DecreaseHbA1c versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Compared with placebo, all once-weekly GLP-1RAs reduced HbA1c and fasting plasma glucose
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized, controlled trials (≥ 24 weeks of follow-up) studying albiglutide, dulaglutide, once-weekly exenatide, semaglutide, and taspoglutide and reporting a cardiometabolic (primary outcome, hemoglobin A1c [HbA1c]) or safety outcome.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2664223301
02HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled once-weekly GLP-1 receptor agonists reduced fasting plasma glucose compared with placebo.
In plain wordsIn adults with type 2 diabetes, once-weekly GLP-1 drugs as a class lowered fasting blood glucose more than placebo.
Peptide
Semaglutide
Outcome
DecreaseFasting plasma glucose versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Compared with placebo, all once-weekly GLP-1RAs reduced HbA1c and fasting plasma glucose
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized, controlled trials (≥ 24 weeks of follow-up) studying albiglutide, dulaglutide, once-weekly exenatide, semaglutide, and taspoglutide and reporting a cardiometabolic (primary outcome, hemoglobin A1c [HbA1c]) or safety outcome.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2664223302
03HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, once-weekly GLP-1 receptor agonists showed marginal or no differences from each other in blood pressure.
In plain wordsIn adults with type 2 diabetes, once-weekly GLP-1 drugs as a class showed little or no difference in blood pressure.
Peptide
Semaglutide
Outcome
No significant changeBlood pressure
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
Clinically marginal or no differences were found for blood pressure, blood lipid levels, and C-reactive protein levels.
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized, controlled trials (≥ 24 weeks of follow-up) studying albiglutide, dulaglutide, once-weekly exenatide, semaglutide, and taspoglutide and reporting a cardiometabolic (primary outcome, hemoglobin A1c [HbA1c]) or safety outcome.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2664223303
04HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, once-weekly GLP-1 receptor agonists showed marginal or no differences from each other in blood lipid levels.
In plain wordsIn adults with type 2 diabetes, once-weekly GLP-1 drugs as a class showed little or no difference in blood lipids.
Peptide
Semaglutide
Outcome
No significant changeBlood lipid levels
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Source sentences
Summary
Clinically marginal or no differences were found for blood pressure, blood lipid levels, and C-reactive protein levels.
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized, controlled trials (≥ 24 weeks of follow-up) studying albiglutide, dulaglutide, once-weekly exenatide, semaglutide, and taspoglutide and reporting a cardiometabolic (primary outcome, hemoglobin A1c [HbA1c]) or safety outcome.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2664223304
05HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, once-weekly GLP-1 receptor agonists showed marginal or no differences from each other in C-reactive protein levels.
In plain wordsIn adults with type 2 diabetes, once-weekly GLP-1 drugs as a class showed little or no difference in C-reactive protein.
Peptide
Semaglutide
Outcome
No significant changeC-reactive protein
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
Clinically marginal or no differences were found for blood pressure, blood lipid levels, and C-reactive protein levels.
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized, controlled trials (≥ 24 weeks of follow-up) studying albiglutide, dulaglutide, once-weekly exenatide, semaglutide, and taspoglutide and reporting a cardiometabolic (primary outcome, hemoglobin A1c [HbA1c]) or safety outcome.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2664223305
06HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, the risk of hypoglycemia was similar among once-weekly GLP-1 receptor agonists.
In plain wordsIn adults with type 2 diabetes, the risk of low blood sugar was similar across once-weekly GLP-1 drugs.
Peptide
Semaglutide
Outcome
No significant changeHypoglycemia risk
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
Among once-weekly GLP-1RAs, the risk for hypoglycemia was similar
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized, controlled trials (≥ 24 weeks of follow-up) studying albiglutide, dulaglutide, once-weekly exenatide, semaglutide, and taspoglutide and reporting a cardiometabolic (primary outcome, hemoglobin A1c [HbA1c]) or safety outcome.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-2664223306

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT03819790

The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians

LMC Diabetes & Endocrinology Ltd.n = 1192 Oct 2018 to 19 Nov 2019

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 25 Feb 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.